Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 14/20 | 0.66 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.66 |
| ▸ | GSPT1 | P15170 | 3/20 | 0.66 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.64 |
| ▸ | CSNK1A1 | P48729 | 4/20 | 0.59 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.56 |
| ▸ | IKZF2 | Q9UKS7 | 7/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1413448 | 0.91 | CRBN (0.67) | CRBNDDB1GSPT1IKZF3CYP2C19 | |
| SCHEMBL1413661 | 0.91 | CRBN (0.68) | CRBNDDB1GSPT1IKZF3CYP2C19 | |
| SCHEMBL1413509 | 0.91 | CRBN (0.77) | CRBNDDB1GSPT1IKZF3CYP2C19 | |
| SCHEMBL30382143 | 0.91 | CRBN (0.72) | CRBNDDB1GSPT1IKZF3CYP2C19 | |
| SCHEMBL1413524 | 0.91 | CRBN (0.72) | CRBNDDB1GSPT1IKZF3CYP2C19 | |
| SCHEMBL1413694 | 0.90 | CRBN (0.61) | CRBNDDB1GSPT1IKZF3CYP2C19 | |
| SCHEMBL1413291 | 0.90 | CRBN (0.61) | CRBNDDB1GSPT1IKZF3CYP2C19 | |
| SCHEMBL30441950 | 0.89 | CRBN (0.65) | CRBNDDB1GSPT1IKZF3CYP2C19 | |
| SCHEMBL1413378 | 0.89 | CRBN (0.72) | CRBNDDB1GSPT1IKZF3CYP2C19 | |
| SCHEMBL30820698 | 0.89 | CRBN (0.67) | CRBNDDB1GSPT1IKZF3CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3925609-A1 | METHODS OF TREATING MULTIPLE MYELOMA WITH IMMUNOMODULATORY COMPOUNDS IN COMBINATION WITH ANTIBODIES | Celgene Corporation (US) | 2021-12-22 | — | — | EP | disclosed |